Tools
Tools
Al Musa, Tarique, Uddin, Akhlaque, Loveday, Catherine, Dobson, Laura E., Igra, Mark, Richards, Fiona, Swoboda, Peter P., Singh, Anvesha, Garg, Pankaj 
ORCID: https://orcid.org/0000-0002-5483-169X, Foley, James R. J., Fent, Graham J., Goddard, Anthony J. P., Malkin, Christopher, Plein, Sven, Blackman, Daniel J., McCann, Gerald P. and Greenwood, John P.
(2019)
Silent cerebral infarction and cognitive function following TAVI: an observational two-centre UK comparison of the first-generation CoreValve and second-generation Lotus valve.
BMJ Open, 9 (1).
ISSN 2044-6055
Preview |
PDF (Published_Version)
- Published Version
Available under License Creative Commons Attribution Non-commercial. Download (832kB) | Preview |
Abstract
Objective: To compare the incidence of silent cerebral infarction and impact on cognitive function following transcatheter aortic valve implantation (TAVI) with the first-generation CoreValve (Medtronic, Minneapolis, Minnesota, USA) and second-generation Lotus valve (Boston Scientific, Natick Massachusetts, USA). Design: A prospective observational study comprising a 1.5 T cerebral MRI scan, performed preoperatively and immediately following TAVI, and neurocognitive assessments performed at baseline, 30 days and 1 year follow-up. Setting: University hospitals of Leeds and Leicester, UK. Patients 66 (80.6±8.0 years, 47% male) patients with high-risk severe symptomatic aortic stenosis recruited between April 2012 and May 2015. Main outcome measures: Incidence of new cerebral microinfarction and objective decline in neurocognitive performance. Results: All underwent cerebral MRI at baseline and immediately following TAVI, and 49 (25 Lotus, 24 CoreValve) completed neurocognitive assessments at baseline, 30 days and 1 year. There was a significantly greater incidence of new cerebral microinfarction observed following the Lotus TAVI (23 (79%) vs 22 (59%), p=0.025) with a greater number of new infarcts per patient (median 3.5 (IQR 7.0) vs 2.0 (IQR 3.0), p=0.002). The mean volume of infarcted cerebral tissue per patient was equivalent following the two prostheses (p=0.166). More patients suffered new anterior (14 (48%) vs 2 (5%), p=0.001) and vertebrobasilar (15 (52%) vs 7 (19%), p=0.005) lesions following Lotus. Lotus was associated with a decline in verbal memory and psychomotor speed at 30 days. However, performance longitudinally at 1 year was preserved in all neurocognitive domains. Conclusions: There was a higher incidence of silent cerebral microinfarction and a greater number of lesions per patient following Lotus compared with CoreValve. However, there was no objective decline in neurocognitive function discernible at 1 year following TAVI with either prosthesis.
| Item Type: | Article |
|---|---|
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 19 Nov 2021 01:40 |
| Last Modified: | 19 Oct 2023 03:09 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/82225 |
| DOI: | 10.1136/bmjopen-2018-022329 |
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |